You are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information
Speaker | Nadia Ashrafi, Ph.D.
Affiliation | Metabolomics Research Group | Corewell Health Research Institute | Corewell Health East William Beaumont University Hospital | Research Scientist
Metabolomic profiling of Cohort Consortium identifies prodromal biomarkers for Parkinson’s disease
Part of the
Corewell Health Metabolomics Symposium
Comprehensive metabolomic profiling of the LRRK2 Cohort Consortium (LCC) identifies prodromal biomarkers for Parkinson’s Disease
Related articles
- Predictive medicine – Transform medicine with metabolomics – part 2 of 5
- N-acetyl-aspartic acid (NAA) – Significant metabolite for brain function, metabolism, and disease
- Preventive medicine – Transform medicine with metabolomics – part 1 of 5
- Citric acid – Key metabolite in energy production, bone health, and disease therapy
- Precision nutrition – Unlocking health through metabolomics